Pionyr Immunotherapeutics Funding: $78M Raised, Series B
Pionyr Immunotherapeutics is based in San Francisco. It has raised $78M in total funding. Latest round: Series B. Backed by OrbiMed, NEA, Sofinnova.
Pionyr Immunotherapeutics funding overview
Pionyr Immunotherapeutics is based in San Francisco. Pionyr Immunotherapeutics has raised $78M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B announced in December 2017. The round record for Pionyr Immunotherapeutics runs through 2017; nothing later has been disclosed. Investors on record include OrbiMed, NEA, Sofinnova, SV Health Investors, Vida Ventures, Trinitas Capital and 2 others. 8 distinct backers are named across the disclosed rounds.
Pionyr Immunotherapeutics at a glance
Total raised
$78M
Latest round
Series B
Latest round date
December 2017
Headquarters
San Francisco
Notable investors
OrbiMed, NEA, Sofinnova, SV Health Investors, Vida Ventures, Trinitas Capital, Mission Bay Capital, Osage University Partners
Frequently asked about Pionyr Immunotherapeutics funding
How much has Pionyr Immunotherapeutics raised?
Pionyr Immunotherapeutics has raised $78M in total disclosed funding across the rounds on record.
Who has invested in Pionyr Immunotherapeutics?
OrbiMed, NEA, Sofinnova, SV Health Investors, Vida Ventures, Trinitas Capital are named among the investors backing Pionyr Immunotherapeutics.
What was the latest Pionyr Immunotherapeutics funding round?
The most recent disclosed round is a Series B, announced in December 2017.
Where is Pionyr Immunotherapeutics based?
Pionyr Immunotherapeutics is based in San Francisco.
When did Pionyr Immunotherapeutics last raise?
The last disclosed Pionyr Immunotherapeutics round closed in December 2017 at Series B.
Pionyr Immunotherapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in San Francisco below to benchmark round size and investor mix.
Companies related to Pionyr Immunotherapeutics (36)
